A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
This research study is looking into a new medicine called SCD-044 for individuals who have moderate to severe eczema, also known as atopic dermatitis. Eczema can cause very itchy, dry skin, and this study aims to see if SCD-044 can significantly improve those symptoms. Researchers will be giving different doses of SCD-044 to some participants, while others will receive a placebo – a dummy tablet that looks like the real medicine but contains no active ingredients. This helps them fairly compare the new medicine. The main goal is to find out if SCD-044 is safe and how well it helps to clear up eczema, particularly looking for a major improvement in skin condition.
At a glance
What is this study about?
Eczema, or atopic dermatitis, is a common skin condition that can make your skin red, itchy, and dry. For some people, it can be quite severe and affect their daily life. Doctors and scientists are always looking for better ways to treat eczema, especially for those cases that are harder to manage.
This particular study is a 'Phase II' clinical trial. This means it's an early stage of testing for a new medicine called SCD-044. At this stage, the main goals are to find out if the medicine is safe to use and if it looks promising for treating eczema. They are also trying to work out the best dose of the medicine to give. To do this, some people will receive different strengths of SCD-044 tablets, and others will receive a 'placebo', which is a tablet that looks the same but doesn't contain any medicine.
The researchers will be carefully observing people in the study to see how their eczema changes over time. They will measure if people experience a big improvement in their eczema symptoms, such as less redness and itching. This study is important because it could help lead to new treatment options for people who suffer from moderate to severe eczema, potentially offering a new way to get relief.
Key takeaways
- Study testing a new medicine (SCD-044) for moderate to severe eczema.
- Compares different doses of SCD-044 against a dummy tablet (placebo).
- Focuses on checking safety and how well the medicine improves eczema symptoms.
- Open to adults aged 18 and over.
- Participation involves regular visits and assessments over about 16 weeks.
- Aims to find better treatments for eczema patients.
Who may be eligible?
To join this study, people generally need to be an adult, aged 18 years or older. There is no upper age limit for taking part.
Both men and women are welcome to participate in the study. The researchers aim to include a diverse group of people to understand how the medicine works across different individuals.
The study is specifically looking for people who have moderate to severe eczema (atopic dermatitis). This means your eczema should be causing significant problems and not just be a very mild case.
- Are you 18 years old or older?
- Do you have moderate to severe eczema (atopic dermatitis)?
- Are you able to attend regular study appointments?
- Are you willing to take a study medicine or placebo tablet as instructed?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would first have a screening visit to check if you meet all the requirements. If you do, you would then be randomly assigned to take one of the different doses of SCD-044 tablets or a placebo tablet. You would take these tablets regularly as instructed by the study team.
Throughout the study, you would need to attend several visits at the study clinic. During these visits, doctors and nurses will assess your eczema, check your general health, and ask about any side effects you might be experiencing. These assessments might include physical examinations and answering questionnaires about your symptoms. You might also need to have blood tests.
The total duration of the study, including all visits and follow-up checks, means you would be involved for a period of several weeks, typically around 16 weeks, to properly assess the effects of the treatment and monitor your health carefully.
Potential risks and benefits
Locations (2)
- —Poland
- —Estonia
Common questions
What is atopic dermatitis?
Atopic dermatitis is the medical name for eczema, a common condition that causes dry, itchy, and inflamed skin.
What does a 'placebo' mean?
A placebo is a 'dummy' tablet that looks just like the study medicine but contains no active ingredients. It helps scientists compare the real medicine's effects.
Why is this called a 'Phase II' study?
Phase II means it's an earlier stage of testing a new medicine. Researchers are mainly looking at its safety and how well it seems to work, and trying to find the best dose.
Will I know if I'm getting the real medicine or the placebo?
This is a 'double-blind' study, meaning neither you nor the study doctors will know whether you are receiving the active medicine or the placebo. This helps make the study as fair as possible.
How long will I be in the study?
The study involves regular visits over approximately 16 weeks to monitor your progress and safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.